Workflow
Klotho Neurosciences, Inc.(KLTO)
icon
Search documents
Klotho Neurosciences, Inc.(KLTO) - 2023 Q2 - Quarterly Report
2023-08-21 21:27
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Units RWODU The Nasdaq Stock Market LLC Common Stock RWOD The Nasdaq Stock Market LLC Warrants RWODW The Nasdaq Stock Market LLC Rights RWODR The Nasdaq Stock Market LLC FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 ...
Klotho Neurosciences, Inc.(KLTO) - 2023 Q1 - Quarterly Report
2023-05-24 20:45
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Units RWODU The Nasdaq Stock Market LLC Common Stock RWOD The Nasdaq Stock Market LLC Warrants RWODW The Nasdaq Stock Market LLC Rights RWODR The Nasdaq Stock Market LLC FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 1 ...
Klotho Neurosciences, Inc.(KLTO) - 2022 Q4 - Annual Report
2023-04-10 21:00
Financial Performance - For the year ended December 31, 2022, the company reported a net income of $1,233,352, which included interest earned of $1,656,478 and a change in fair value of warrant liabilities of $555,917[61]. - The company had cash of $340,962 and working capital of $299,788 as of December 31, 2022, excluding income tax and franchise tax payable[68]. IPO Details - The company completed its IPO on April 4, 2022, raising gross proceeds of $100,000,000 from the sale of 10,000,000 Public Units at $10.00 each[62]. - An additional 1,500,000 Public Units were sold through an over-allotment option, generating gross proceeds of $15,000,000[63]. - The company incurred total transaction costs of $8,365,339 related to the IPO, including $2,875,000 in underwriting fees and $4,312,500 in deferred underwriting fees[66]. - Offering costs related to the IPO were charged to stockholders' equity upon completion, allocated based on the relative fair values of public shares, warrants, and rights[86]. Trust Account and Business Combination - As of December 31, 2022, the Trust Account held marketable securities valued at $117,806,478, consisting of U.S. government securities[67]. - The company plans to utilize funds from the Trust Account primarily for acquiring a target business and covering related expenses[67]. - The company has until April 4, 2023, to complete a Business Combination, or it will face mandatory liquidation[69]. Debt and Financial Obligations - The company has no long-term debt or capital lease obligations as of the reporting date[71]. - The company is subject to a 1% excise tax on stock repurchases after December 31, 2022, which may affect the attractiveness of business combinations[92]. Regulatory and Compliance Matters - The company is considered a "foreign person" under CFIUS regulations, which may limit potential business combination opportunities and require mandatory filings[93]. - The company evaluated its disclosure controls and procedures as effective as of December 31, 2022[101]. - The company does not expect its disclosure controls and procedures to prevent all errors and instances of fraud, providing only reasonable assurance[102]. - There were no changes in internal control over financial reporting during the most recent fiscal quarter that materially affected the company's internal controls[103]. Accounting and Reporting - The company accounts for public warrants as equity and private warrants as liabilities, with the assessment conducted at issuance and quarterly thereafter[82][83]. - Common stock subject to possible redemption is classified as temporary equity and presented at redemption value, with adjustments recognized immediately[84]. - The company reported compliance with FASB ASC 260 for net income (loss) per share, allocating undistributed income based on the weighted average number of shares outstanding[85]. - As an emerging growth company, the company is allowed to delay the adoption of new accounting standards, which may affect comparability with non-emerging growth companies[98][99]. Administrative Agreements - The company has entered into an administrative services agreement to pay the Sponsor $10,000 per month for support services[73]. Off-Balance Sheet Arrangements - The company has no off-balance sheet arrangements as of December 31, 2022[97].
Klotho Neurosciences, Inc.(KLTO) - 2022 Q2 - Quarterly Report
2022-08-15 21:08
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41340 Redwoods Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware 86-2727441 (State or other juri ...
Klotho Neurosciences, Inc.(KLTO) - 2022 Q1 - Quarterly Report
2022-05-16 20:33
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41340 Redwoods Acquisition Corp. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpo ...